- Home
- GOVX vs CJMB Comparison
GOVX vs CJMB Comparison
Compare GOVX & CJMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- CJMB
- Stock Information
- Founded
- GOVX 2001
- CJMB 2007
- Country
- GOVX United States
- CJMB United States
- Employees
- GOVX N/A
- CJMB N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- CJMB
- Sector
- GOVX Health Care
- CJMB
- Exchange
- GOVX Nasdaq
- CJMB NYSE
- Market Cap
- GOVX 19.5M
- CJMB 18.8M
- IPO Year
- GOVX N/A
- CJMB 2025
- Fundamental
- Price
- GOVX $1.67
- CJMB $5.54
- Analyst Decision
- GOVX Strong Buy
- CJMB
- Analyst Count
- GOVX 5
- CJMB 0
- Target Price
- GOVX $14.20
- CJMB N/A
- AVG Volume (30 Days)
- GOVX 569.4K
- CJMB 891.7K
- Earning Date
- GOVX 03-03-2025
- CJMB 01-01-0001
- Dividend Yield
- GOVX N/A
- CJMB N/A
- EPS Growth
- GOVX N/A
- CJMB N/A
- EPS
- GOVX N/A
- CJMB N/A
- Revenue
- GOVX $3,090,161.00
- CJMB $6,884,783.00
- Revenue This Year
- GOVX N/A
- CJMB N/A
- Revenue Next Year
- GOVX $150.51
- CJMB N/A
- P/E Ratio
- GOVX N/A
- CJMB N/A
- Revenue Growth
- GOVX N/A
- CJMB N/A
- 52 Week Low
- GOVX $1.09
- CJMB $3.38
- 52 Week High
- GOVX $11.18
- CJMB $7.76
- Technical
- Relative Strength Index (RSI)
- GOVX 37.32
- CJMB N/A
- Support Level
- GOVX $1.50
- CJMB N/A
- Resistance Level
- GOVX $1.79
- CJMB N/A
- Average True Range (ATR)
- GOVX 0.13
- CJMB 0.00
- MACD
- GOVX 0.01
- CJMB 0.00
- Stochastic Oscillator
- GOVX 29.82
- CJMB 0.00
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.